Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

BOVA UK issues statement on omeprazole concerns
BOVA Aus and BOVA UK have switched supplier for the excipient that was responsible for the traces of testosterone.
Company changes excipient responsible for testosterone traces 

Drug company BOVA UK has issued a statement after testosterone was identified in a vial of its long-acting omeprazole injection in June.

Supply of the product ceased in Australia after the initial discovery by the New South Wales racing authority.

Samples tested by the British Horseracing Authority (BHA) confirmed the issue extended to the UK and the racing body recently advised against using injectible omeprazole in racehorses.

BOVA Aus and BOVA UK have carried out their own investigations and switched their supplier for the excipient that was responsible for the traces of testosterone. The company said all testing done on the new supplier has shown no traces of testosterone.

Independent testing
Nick Bova, managing director of BOVA UK, said: “We had no explanation for how contamination could have occurred at that time as we do not handle testosterone.

“The Omeprazole active pharmaceutical ingredient (API) is subject to ID testing on arrival at our licensed manufacturing facilities as well as material approval checks and compliance checks to set specifications in order to ensure that it complies with international standards.”

Through an independent testing process, it was revealed that one of the excipient raw ingredients contained testosterone at levels that are well within accepted international standards for impurities. Levels of testosterone found in the end product were confirmed by external laboratories to be 400-700 picograms per ml.

Supplier change
Mr Bova continued: “We have consulted veterinary pharmacologists and sports medicine specialists who have given their opinion that these levels are within accepted standards and could neither have a clinical effect nor result in a positive blood or urine test for testosterone in competition horses.

“The levels of testosterone within the product are inconsequential compared to endogenous production in mares and geldings as well as stallions and higher levels are found frequently in feed and water sources; testosterone being a common compound produced by humans and animals from multiple organs…

He added: “Although the level of impurities is well within the accepted international standard, we have changed the supplier of the excipient in question. We have established an analytical method capable of testing down to picogram levels, which has been used to test the end product to ensure there are no further concerns with future batches.”

“We sincerely apologise for any inconvenience this issue may have caused. Many vets and horse owners now rely on long acting injectable omeprazole for horses that do not respond to oral treatment and we can reassure anyone who has used the product in recent months, or has product that they are due to use, that they can do so safely. However, we would draw attention to the recent statement from the BHA that they do not wish the product to be used in horses in training currently.”

Become a member or log in to add this story to your CPD history

Webinar to explore AMR in vet dentistry

News Story 1
 The WSAVA has invited veterinary professionals to a webinar on responsible antibiotic usage in dentistry.

On 19 November 2025, at 1am, Dr J Scott Weese and Dr Brooke Niemiec will share the latest advice for antimicrobial use. They will present research on oral bacterology, and explain how attendees can choose appropriate antibiotics.

The session will cover pre-, intra- and post-operative guidelines, with recommendations for various pathologies.

The webinar is designed to support veterinary professionals to make informed decisions and tackle antimicrobial resistance.

Attendees can register here

Click here for more...
News Shorts
Bluetongue reaches Wales for first time in 2025

The Animal and Plant Health Agency (APHA) has revealed that bluetongue has been confirmed in Wales for the first time in 2025.

In their latest statistics, APHA records a total of 109 cases of BTV-3 or BTV-8 in Great Britain in the 2025-2026 vector season.

The total number of BTV-3 cases in Great Britain this season is 107. This includes 103 cases within the England restricted zone and four cases in Wales.

There has also been two cases of BTV-8, which were both in Cornwall.

As a result of the cases in Wales, a Temporary Control Zone (TCZ) is enforced in Monmouthshire. Animals can move freely under general license within the England Restricted Zone, however animals with suspected bluetongue must stay on their holding.

All premises testing positive for blue tongue can be viewed on this map.